The Forum programme will be crafted around the theme ‘Partnering for global health research innovation and impact in Africa – Celebrating EDCTP: two decades and beyond.’ At this Forum we will be reflecting on the achievements, impact, and challenges of the past 20 years of EDCTP, whilst looking forward to opportunities under the Global Health EDCTP3 programme.
The Eleventh EDCTP Forum will be held in a hybrid way, with the possibility to attend the full programme online, with a selection of sessions available online.
Satellite session
Nothing less than health for all: Essential elements for sustainable NTD control and elimination through medical innovation
Date: Friday, 10 November 2023
Time: 8:00-9:00 CET
| Introduction and welcome Luis Pizarro, Executive Director, DNDi |
| Innovative R&D and built capacity for the elimination of sleeping sickness Florent Mbo, Access Leader and HAT Platform Coordinator, DNDi |
| Visceral leishmaniasis: on the brink of game-changing treatment options Ahmed M Musa, Professor of Immunology and Infectious Diseases, Institute of Endemic Diseases, University of Khartoum |
| Helminths: Partnering for the pipeline Coralie Martin, Professor, Parasites & Protists, National Museum of Natural History, Paris |
| Nothing less than health for all – what is at stake when we talk about partnership and innovation for NTDs Spring Gombe, Partner, Market Access Africa |
Parallel session
Neglected infectious diseases: diagnosis, treatment and prevention
Date: Thursday, 9 November 2023
Time: 10:30-12:30 CET
| Improved molecular diagnosis of visceral leishmaniasis (VL) using the mini direct on blood PCR Nucleic Acid Lateral Flow Immunoassay (dbPCR-NALFIA) Henk Schallig, Senior Researcher, Academic Medical Center | |
| Development of a CAA/CCA duplex test for improved diagnosis of human schistosomiasis Pytsje Hoekstra, Postdoctoral Researcher, Leiden University Medical Center | |
| Skin diseases and their frequency patterns in skin camps in PEP4LEP implementing districts in Tanzania, preliminary results Nelly Mwageni, Catholic University of Health and Allied Sciences | |
| A phase II/III multicenter randomized clinical trial evaluating the safety and efficacy of a single and three-day albendazole-ivermectin fixed-dose versus albendazole to treat soil transmitted helminthiases Jose Muñoz, Associate Research Professor, ISGLOBAL | |
| Towards an arsenic-free oral treatment for human African trypanosomiasis due to T.b. rhodesiense: a new tool for disease elimination Olaf Valverde, Clinical Project Leader (HAT), DNDi | |
| Molecular diagnostic tests specificities and their contribution for HAT postelimination monitoring in Burkina Faso and Côte d’Ivoire Charlie Franck Alfred Compaoré, Institut de Recherche Pour Le Développement |
Posters
Date: Thursday, 9 November 2023
Time: 12:45-14:00 CET
| Predicting disease effect on the pharmacokinetics (PK) of sustained and immediate release formulations of flucytosine by applying physiologically based pharmacokinetic (PBPK) modeling Eriksson J, Sjögren E, Gillon JV, Goyal V, Robinson S, Caplain H, Ribeiro I, Chenel M* |
Date: Friday, 10 November 2023
Time: 12:45-14:00 CET
| Capacity development to facilitate delivery and uptake of a new medical intervention: Fexinidazole oral treatment for the elimination of human African trypanosomiasis Mbo F*, Valverde O, Ngolo D, Mwamba E, Mamadou C, Nyembo A, Bilonda A |
More information
DNDi resources of interest
- Watch our short films:
- DNDi Strategic Plan 2021-2028
- DNDi 2022 Annual Report
- New hope for leishmaniasis
- Disease factsheets:
